Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial.
Sign Up to like & getrecommendations! Published in 2022 at "Seminars in arthritis and rheumatism"
DOI: 10.1016/j.semarthrit.2022.151955
Abstract: OBJECTIVE To investigate treatment efficacy of long-term abatacept treatment in pSS patients. METHODS The single-centre ASAP-III trial consisted of two phases: the randomised, double-blind, placebo-controlled phase (1:1 randomisation) from baseline to week 24, of which… read more here.
Keywords: abatacept treatment; iii trial; long term; treatment ... See more keywords